Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alpharma gets U.S. rights to Diractin

Idea (Munich, Germany) granted ALO exclusive U.S. rights to commercialize Diractin (formerly IDEA-033) to treat

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE